ALECTINIB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 2,932 adverse event reports in the FDA FAERS database where ALECTINIB was used for Lung neoplasm malignant.
Most Reported Side Effects for ALECTINIB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Death | 702 | 7.7% | 697 | 23 |
| Fatigue | 618 | 6.8% | 12 | 78 |
| Constipation | 525 | 5.7% | 16 | 77 |
| Off label use | 495 | 5.4% | 43 | 43 |
| No adverse event | 488 | 5.3% | 0 | 2 |
| Disease progression | 366 | 4.0% | 64 | 31 |
| Rash | 312 | 3.4% | 5 | 54 |
| Dyspnoea | 296 | 3.2% | 22 | 110 |
| Drug ineffective | 269 | 2.9% | 47 | 25 |
| Myalgia | 268 | 2.9% | 1 | 21 |
| Anaemia | 267 | 2.9% | 9 | 47 |
| Asthenia | 258 | 2.8% | 15 | 38 |
| Weight increased | 237 | 2.6% | 2 | 18 |
| Nausea | 225 | 2.5% | 10 | 59 |
| Diarrhoea | 204 | 2.2% | 13 | 40 |
Other Indications for ALECTINIB
Non-small cell lung cancer (1,946)
Product used for unknown indication (1,303)
Non-small cell lung cancer metastatic (627)
Lung adenocarcinoma (575)
Lung cancer metastatic (421)
Bronchial carcinoma (339)
Neoplasm malignant (211)
Metastases to central nervous system (120)
Lung carcinoma cell type unspecified stage 0 (71)
Metastases to bone (71)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)
ATEZOLIZUMAB (1,262)